Olipudase alfa

Drug Profile

Olipudase alfa

Alternative Names: GZ-402665; Recombinant human acid sphingomyelinase - Sanofi Genzyme; rhASM - Sanofi Genzyme

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Genzyme Corporation
  • Developer Genzyme Corporation; Sanofi Genzyme
  • Class Sphingomyelin phosphodiesterases
  • Mechanism of Action Sphingomyelin phosphodiesterase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Niemann-Pick diseases
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Niemann-Pick disease type B
  • No development reported Niemann-Pick disease type A

Most Recent Events

  • 01 Dec 2015 Phase-II/III clinical trials in Niemann-Pick disease type B in Spain, Netherlands (IV) after December 2015
  • 05 Oct 2015 Phase-I/II clinical trials in Niemann-Pick disease type B (In adolescents, In children, In infants) in USA and France (IV)
  • 05 Oct 2015 Phase-II clinical trials in Niemann-Pick disease type B in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top